As novel agents targeting IFN-I are already in clinical trials [40], flow-cytometry analysis of CD64 expression may be a convenient and rapid approach for estimating IFN-I levels in SLE patients. This evidence concerns the gene FCGR1A and systemic lupus erythematosus.